Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Dietrich

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Breast (Edinburgh, Scotland)|March 25, 2014
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)Arnoud J Templeton, Karin Ribi, Christian Surber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
Chemico-Biological Interactions|May 7, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
ALTEX|November 1, 2013
A roadmap for hazard monitoring and risk assessment of marine biotoxins on the basis of chemical and biological test systemsMardas Daneshian, Luis M Botana, Marie-Yasmine Dechraoui Bottein, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Environmental Toxicology and Pharmacology|May 12, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Journal of Toxicology and Environmental Health. Part A|June 20, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Archives of Toxicology|June 10, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Breast (Edinburgh, Scotland)|March 25, 2014
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)Arnoud J Templeton, Karin Ribi, Christian Surber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
Chemico-Biological Interactions|May 7, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
ALTEX|November 1, 2013
A roadmap for hazard monitoring and risk assessment of marine biotoxins on the basis of chemical and biological test systemsMardas Daneshian, Luis M Botana, Marie-Yasmine Dechraoui Bottein, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|May 4, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Environmental Toxicology and Pharmacology|May 12, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Journal of Toxicology and Environmental Health. Part A|June 20, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Archives of Toxicology|June 10, 2020
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Herman Autrup, Frank A Barile, Sir Colin Berry, et al.
Pageof 7